Side-by-side comparison of AI visibility scores, market position, and capabilities
SF AI healthcare administration automating medical coding, billing, and claims for clinics with 30% cost savings and 20% fewer denials; YC S23 $4.5M competing with Waystar for revenue cycle management automation.
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Graphene Ventures, and Orange Collective — providing medical clinics and healthcare providers with autonomous AI agents that handle medical coding, billing, claims submission, denial management, scheduling coordination, and patient payment collection, automating 80%+ of the repetitive administrative tasks that currently consume 30-40% of healthcare provider revenue in overhead costs. Founded in 2023 by Daniyal Afzal, James Oswald, and Kevin Cheng, Decoda's AI agents deliver 30% reduction in coding costs, 20% reduction in claim denials, and claims processing in seconds versus the days that manual coding and submission require.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.